MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer

International Journal of Urology

Volumn 22, Issue 9, 2015, Pages 867-877

  Nishikawa, Rika ^a   Goto, Yusuke ^a   Kurozumi, Akira ^a   Matsushita, Ryosuke ^b   Enokida, Hideki ^b   Kojima, Satoko ^c   Naya, Yukio ^c   Nakagawa, Masayuki ^b   Ichikawa, Tomohiko ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

microRNA 205; Centromere protein F; MicroRNA; Prostate cancer; Tumor suppressor

Indexed keywords

CENTROMERE PROTEIN F; MICRORNA 205; MINICHROMOSOME MAINTENANCE PROTEIN 7; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; MICRORNA; MIRN205 MICRORNA, HUMAN; NONHISTONE PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURGERY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; SIGNAL TRANSDUCTION; TUMOR INVASION; VERY ELDERLY; CELL MOTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MICROFILAMENT PROTEINS; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84940795807     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12829     Document Type: Article

References (31)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
2. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 2008; 9: 102-14.
3. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19: 92-105.
4. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009; 27: 5848-56.
5. Fuse M, Kojima S, Enokida H et al. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J. Hum. Genet. 2012; 57: 691-9.
6. Kojima S, Chiyomaru T, Kawakami K et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br. J. Cancer 2012; 106: 405-13.
7. Kojima S, Enokida H, Yoshino H et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet. 2013; 59: 78-87.
8. Goto Y, Nishikawa R, Kojima S et al. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014; 588: 1973-82.
9. Goto Y, Kojima S, Nishikawa R et al. The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget 2014; 5: 7748-59.
10. Nishikawa R, Goto Y, Kojima S et al. Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int. J. Oncol. 2014; 45: 401-10.
11. Nishikawa R, Goto Y, Sakamoto S et al. Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci. 2014; 105: 802-11.
12. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63: 11-30.
13. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 2011; 8: 357-68.
14. Chi KN, Bjartell A, Dearnaley D et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur. Urol. 2009; 56: 594-605.
15. Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. The functional significance of aberrant expressed microRNAs in prostate cancer. Int. J. Urol. 2015; 22: 242-52.
16. Qin AY, Zhang XW, Liu L et al. MiR-205 in cancer: an angel or a devil? Eur. J. Cell Biol. 2013; 92: 54-60.
17. Greene SB, Herschkowits JI, Rosen JM. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol. 2010; 7: 300-4.
18. Hulf T, Sibbritt T, Wiklund ED et al. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2013; 32: 2891-9.
19. Gandellini P, Profumo V, Casamichele A et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ. 2012; 19: 1750-60.
20. Majid S, Dar AA, Saini S et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010; 116: 5637-49.
21. Tucci P, Agostini M, Grespi F et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl Acad. Sci. USA 2012; 109: 15312-7.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
23. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J. Cell Biol. 1995; 130: 507-18.
24. Johnson VL, Scott MI, Holt SV, Hussein D, Taylor SS. Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. J. Cell Sci. 2004; 117: 1577-89.
25. Varis A, Salmela AL, Kallio MJ. Cenp-F (mitosin) is more than a mitotic marker. Chromosoma 2006; 115: 288-95.
26. Kim HE, Kim DG, Lee KJ et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS ONE 2012; 7: e43223.
27. Chen WB, Cheng XB, Ding W et al. Centromere protein F and survivin are associated with high risk and a poor prognosis in colorectal gastrointestinal stromal tumours. J. Clin. Pathol. 2011; 64: 751-5.
28. Aytes A, Mitrofanova A, Lefebvre C et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 2014; 25: 638-51.
29. Dai Y, Liu L, Zeng T et al. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2013; 436: 711-8.
30. Ren B, Yu G, Tseng GC et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006; 25: 1090-8.
31. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J. Clin. Pathol. 2004; 57: 1057-62.